Literature DB >> 3907828

Superior vena cava obstruction syndrome: recommendations for management.

J P Sculier, R Feld.   

Abstract

The main cause of superior vena cava syndrome (SVCS) is malignant disease. However, multiple other diseases must be considered in the differential diagnosis and a new entity, SVCS due to central venous catheters, represents an etiology of increasing importance. SVCS due to malignancy should not be considered as a radiotherapeutic emergency. Careful management including invasive procedures such as mediastinoscopy to make a definite diagnosis should be performed when necessary by skilled practitioners, as specific therapy depends on a histologic diagnosis. Irradiation remains the standard treatment for many solid tumours, particularly non-small cell lung cancer. For chemosensitive tumours such as small cell bronchogenic carcinoma or lymphoma, chemotherapy can be recommended as initial treatment, and it is associated with high regression rates of the SVCS. In the case of a recent thrombosis of the superior vena cava, fibrinolytics may be applied as suggested by the experience obtained with central venous catheters.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3907828     DOI: 10.1016/0305-7372(85)90038-6

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  4 in total

1.  [Facial edemas in a 61-year old patient].

Authors:  S Kappes; M Kunz; G Klautke; H Terpe; G Gross
Journal:  Hautarzt       Date:  2002-09       Impact factor: 0.751

2.  Central venous catheter associated thrombosis of major veins: thrombolytic treatment with recombinant tissue plasminogen activator.

Authors:  S Rodenhuis; L G van't Hek; L T Vlasveld; R Kröger; R Dubbelman; R G van Tol
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

Review 3.  Superior vena cava syndrome.

Authors:  L J Wudel; J C Nesbitt
Journal:  Curr Treat Options Oncol       Date:  2001-02

Review 4.  Intensive care and oncology.

Authors:  J P Sculier
Journal:  Support Care Cancer       Date:  1995-03       Impact factor: 3.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.